The significance of the expression of dihydropyrimidine dehydrogenase in prostate cancer

BJU International

Volumn 99, Issue 3, 2007, Pages 663-668

  Li, Yongnan ^a   Mizutani, Yoichi ^a   Shiraishi, Takumi ^a   Nakamura, Terukazu ^a   Mikami, Kazuya ^a   Takaha, Natsuki ^a   Okihara, Koji ^a   Kawauchi, Akihiro ^a   Sakai, Toshiyuki ^a   Miki, Tsuneharu ^a  

^a KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

Author keywords

5 FU; DPD; Immunohistochemistry; Prostate cancer

Indexed keywords

5 CHLORO 2,4 DIHYDROXYPYRIDINE; DIHYDROPYRIMIDINE DEHYDROGENASE; FLUOROURACIL; OXIDOREDUCTASE INHIBITOR; TEGAFUR;

ADJUVANT THERAPY; ADULT; AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER RECURRENCE; CANCER SURVIVAL; CANCER TISSUE; CLINICAL ARTICLE; COMBINATION CHEMOTHERAPY; COMPARATIVE STUDY; CONTROLLED STUDY; CYTOTOXICITY; FOLLOW UP; HORMONAL THERAPY; HUMAN; HUMAN TISSUE; IMMUNE DEFICIENCY; IMMUNOHISTOCHEMISTRY; MALE; MONOTHERAPY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROGNOSIS; PROSTATE; PROSTATE CANCER; PROSTATECTOMY; PROTEIN EXPRESSION; PROTEIN FUNCTION; SURVIVAL TIME; TUMOR GROWTH;

AGED; ANIMALS; ANTIMETABOLITES, ANTINEOPLASTIC; CHEMOTHERAPY, ADJUVANT; DIHYDROURACIL DEHYDROGENASE (NADP); DISEASE-FREE SURVIVAL; FLUOROURACIL; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MICE; MICE, SCID; MIDDLE AGED; NEOADJUVANT THERAPY; PROGNOSIS; PROSTATECTOMY; PROSTATIC NEOPLASMS; PYRIDINES; TUMOR CELLS, CULTURED;

EID: 33846901882     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2006.06606.x     Document Type: Article

References (22)

1. Ezzeldin H, Johnson MR, Okamoto Y, Diasio RB. Denaturing high performance liquid chromatography analysis of the DPYD gene in patients with lethal 5-fluorouracil toxicity. Clin Cancer Res 2003; 9: 3021-8
2. Ezzeldin HH, Lee AM, Mattison LK, Diasio RB. Methylation of the DPYD promoter: an alternative mechanism for dihydropyrimidine dehydrogenase deficiency in cancer patients. Clin Cancer Res 2005; 11: 8699-705
3. Mizutani Y, Wada H, Fukushima M et al. The significance of dihydropyrimidine dehydrogenase (DPD) activity in bladder cancer. Eur J Cancer 2001; 37: 569-75
4. Wei X, McLeod HL, McMurrough J, Gonzalez FJ, Fernandez-Salguero P. Molecular basis of the human dihydropyrimidine dehydrogenase deficiency and 5-fluorouracil toxicity. J Clin Invest 1996; 98: 610-5
5. Johnson MR, Diasio RB. Importance of dihydropyrimidine dehydrogenase (DPD) deficiency in patients exhibiting toxicity following treatment with 5-fluorouracil. Adv Enzyme Regul 2001; 41: 151-7
6. Kobayashi H, Koike T, Nakatsuka A et al. Dihydropyrimidine dehydrogenase expression predicts survival outcome and chemosensitivity to 5-fluorouracil in patients with oral squamous cell carcinoma. Oral Oncol 2005; 41: 38-47
7. Canellakis ES. Pyrimidine metabolism. I. Enzymatic pathways of uracil and thymidine degradation. J Biol Chem 1956; 221: 315-22
8. Fink RM, Fink K, Henderson RB. Beta-amino acid formation by tissue slices incubated with pyrimidines. J Biol Chem 1953; 201: 349-55
9. Naguib FN, el Kouni MH, Cha S. Enzymes of uracil catabolism in normal and neoplastic human tissues. Cancer Res 1985; 45: 5405-12
10. Ho DH, Townsend L, Luna MA, Bodey GP. Distribution and inhibition of dihydrouracil dehydrogenase activities in human tissues using 5-fluorouracil as a substrate. Anticancer Res 1986; 6: 781-4
11. Queener SF, Morris HP, Weber G. Dihydrouracil dehydrogenase activity in normal, differentiating and regenerating liver and hepatomas. Cancer Res 1971; 31: 1004-9
12. Etienne MC, Cheradame S, Fischel JL et al. Response to fluorouracil therapy in cancer patients: the role of tumoral dihydropyrimidine dehydrogenase activity. J Clin Oncol 1995; 13: 1663-70
13. McLeod HL, Sludden J, Murray GI et al. Characterization of dihydropyrimidine dehydrogenase in human colorectal tumours. Br J Cancer 1998; 77: 461-5
14. Huang CL, Yokomise H, Kobayashi S, Fukushima M, Hitomi S, Wada H. Intratumoral expression of thymidylate synthase and dihydropyrimidine dehydrogenase in non-small cell lung cancer patients treated with 5-FU-based chemotherapy. Int J Oncol 2000; 17: 47-54
15. Horiguchi J, Takei H, Koibuchi Y et al. Prognostic significance of dihydropyrimidine dehydrogenase expression in breast cancer. Br J Cancer 2002; 86: 222-5
16. Oi K, Makino M, Ozaki M et al. Immunohistochemical dihydropyrimidine dehydrogenase expression is a good prognostic indicator for patients with Dukes' C colorectal cancer. Anticancer Res 2004; 24: 273-9
17. Ishikawa Y, Kubota T, Otani Y et al. Dihydropyrimidine dehydrogenase activity and messenger RNA levels may be related to the antitumor effect of 5-fluorouracil on human tumor xenografts in nude mice. Clin Cancer Res 1999; 5: 883-9
18. Mizutani Y, Wada H, Yoshida O et al. Significance of thymidylate synthase activity in renal cell carcinoma. Clin Cancer Res 2003; 9: 1453-60
19. Babaian RJ, Troncoso P, Bhadkamkar VA, Johnston DA. Analysis of clinicopathologic factors predicting outcome after radical prostatectomy. Cancer 2001; 91: 1414-22
20. Takechi T, Fujioka A, Matsushima E, Fukushima M. Enhancement of the antitumour activity of 5-fluorouracil (5-FU) by inhibiting dihydropyrimidine dehydrogenase activity (DPD) using 5-chloro-2,4-dihydroxypyridine (CDHP) in human tumour cells. Eur J Cancer 2002; 38: 1271-7
21. Nozawa H, Tsukui H, Nishida K, Yakumaru K, Nagawa H, Sekikawa T. Dihydropyrimidine dehydrogenase expression in preoperative biopsy and surgically resected specimens of gastric carcinoma. Cancer Chemother Pharmacol 2002; 49: 267-73
22. Tuchman M, O'Dea RF, Ramnaraine ML, Mirkin BL. Pyrimidine base degradation in cultured murine C-1300 neuroblastoma cells and in situ tumors. J Clin Invest 1988; 81: 425-30